Cipla Share Price
Sector: Biotechnology & Drugs
1509.80 +6.95 (0.46%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1500.00
Today’s High
1519.10
52 Week Low
1310.05
52 Week High
1702.00
1510.00 +7.60 (0.51%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1500.00
Today’s High
1518.00
52 Week Low
1335.00
52 Week High
1702.05
Key Metrics
- Market Cap (In Cr) 121919.33
- Beta 0.43
- Div. Yield (%) 0.87
- P/B 3.89
- TTM P/E 22.09
- Peg Ratio 0.82
- Sector P/E 22.42
- D/E 0
- Open Price 1519.1
- Prev Close 1502.85
Cipla Analysis
Price Analysis
-
1 Week-0.07%
-
3 Months-0.58%
-
6 Month1.81%
-
YTD-1.74%
-
1 Year-0.13%
Risk Meter
- 23% Low risk
- 23% Moderate risk
- 23% Balanced Risk
- 23% High risk
- 23% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 8
- 8
- 7
- 7
- Buy
- 11
- 11
- 12
- 12
- Hold
- 8
- 8
- 8
- 8
- Sell
- 6
- 6
- 6
- 4
- Strong Sell
- 0.00
- 0.00
- 0.00
- 1
- Total
- 33
- 33
- 33
- 32
Cipla News
Hindustan Unilever, Vedanta, among others to trade ex-dividend next week
6 min read . 22 Jun 2025Ozempic, a patent challenge, and $25 bn race for India’s weight-loss drug market
10 min read . 19 Jun 2025Cipla Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 27547.62
- Selling/ General/ Admin Expenses Total
- 9245.18
- Depreciation/ Amortization
- 993.38
- Other Operating Expenses Total
- 623.92
- Total Operating Expense
- 21391.03
- Operating Income
- 6156.59
- Net Income Before Taxes
- 6820.81
- Net Income
- 5272.52
- Diluted Normalized EPS
- 65.19
- Period
- 2025
- Total Assets
- 37387.04
- Total Liabilities
- 6193.59
- Total Equity
- 31193.45
- Tangible Book Valueper Share Common Eq
- 324.5
- Period
- 2025
- Cashfrom Operating Activities
- 5004.98
- Cashfrom Investing Activities
- -3691.14
- Cashfrom Financing Activities
- -1292.79
- Net Changein Cash
- 30.31
- Period
- 2024
- Total Revenue
- 25774.09
- Selling/ General/ Admin Expenses Total
- 8433.06
- Depreciation/ Amortization
- 939.1
- Other Operating Expenses Total
- 649.33
- Total Operating Expense
- 20714.98
- Operating Income
- 5059.11
- Net Income Before Taxes
- 5701.9
- Net Income
- 4121.55
- Diluted Normalized EPS
- 53.76
- Period
- 2024
- Total Assets
- 32717.82
- Total Liabilities
- 6011.39
- Total Equity
- 26706.43
- Tangible Book Valueper Share Common Eq
- 272.41
- Period
- 2024
- Cashfrom Operating Activities
- 4133.91
- Cashfrom Investing Activities
- -2988.03
- Cashfrom Financing Activities
- -1200.43
- Net Changein Cash
- -48.99
- Period
- 2023
- Total Revenue
- 22753.12
- Selling/ General/ Admin Expenses Total
- 7507.04
- Depreciation/ Amortization
- 1017.83
- Other Operating Expenses Total
- 511.6
- Total Operating Expense
- 19047.03
- Operating Income
- 3706.09
- Net Income Before Taxes
- 4038.35
- Net Income
- 2801.91
- Diluted Normalized EPS
- 37.37
- Period
- 2023
- Total Assets
- 29463.28
- Total Liabilities
- 6055.5
- Total Equity
- 23407.78
- Tangible Book Valueper Share Common Eq
- 234.08
- Period
- 2023
- Cashfrom Operating Activities
- 3237.65
- Cashfrom Investing Activities
- -2388.51
- Cashfrom Financing Activities
- -958.29
- Net Changein Cash
- -96.78
- Period
- 2022
- Total Revenue
- 21763.34
- Selling/ General/ Admin Expenses Total
- 6908.86
- Depreciation/ Amortization
- 987.83
- Other Operating Expenses Total
- 463.91
- Total Operating Expense
- 18430.6
- Operating Income
- 3332.74
- Net Income Before Taxes
- 3493.27
- Net Income
- 2516.75
- Diluted Normalized EPS
- 33.28
- Period
- 2022
- Total Assets
- 27101.12
- Total Liabilities
- 6259.43
- Total Equity
- 20841.69
- Tangible Book Valueper Share Common Eq
- 198.32
- Period
- 2022
- Cashfrom Operating Activities
- 3325.9
- Cashfrom Investing Activities
- -1871.88
- Cashfrom Financing Activities
- -1599.79
- Net Changein Cash
- -132.32
- Period
- 2021
- Total Revenue
- 19159.59
- Selling/ General/ Admin Expenses Total
- 6031.69
- Depreciation/ Amortization
- 1000.57
- Other Operating Expenses Total
- 399.33
- Total Operating Expense
- 15960.05
- Operating Income
- 3199.54
- Net Income Before Taxes
- 3290.06
- Net Income
- 2404.87
- Diluted Normalized EPS
- 30.35
- Period
- 2021
- Total Assets
- 25151.89
- Total Liabilities
- 6825.36
- Total Equity
- 18326.53
- Tangible Book Valueper Share Common Eq
- 167.29
- Period
- 2021
- Cashfrom Operating Activities
- 3755.2
- Cashfrom Investing Activities
- -2387.18
- Cashfrom Financing Activities
- -1329.9
- Net Changein Cash
- 50.91
- Period
- 2020
- Total Revenue
- 17131.99
- Selling/ General/ Admin Expenses Total
- 6203.89
- Depreciation/ Amortization
- 1097.31
- Other Operating Expenses Total
- 421.32
- Total Operating Expense
- 15091.19
- Operating Income
- 2040.8
- Net Income Before Taxes
- 2178.18
- Net Income
- 1546.52
- Diluted Normalized EPS
- 19.8
- Period
- 2020
- Total Assets
- 23662.56
- Total Liabilities
- 7899.56
- Total Equity
- 15763
- Tangible Book Valueper Share Common Eq
- 135.56
- Period
- 2020
- Cashfrom Operating Activities
- 3068.45
- Cashfrom Investing Activities
- 104.04
- Cashfrom Financing Activities
- -2948.82
- Net Changein Cash
- 234.02
- Period
- 2019
- Total Revenue
- 16362.41
- Selling/ General/ Admin Expenses Total
- 5710.55
- Depreciation/ Amortization
- 1095.66
- Other Operating Expenses Total
- 495.46
- Total Operating Expense
- 14585.29
- Operating Income
- 1777.12
- Net Income Before Taxes
- 2079.14
- Net Income
- 1527.7
- Diluted Normalized EPS
- 20.97
- Period
- 2019
- Total Assets
- 23963.32
- Total Liabilities
- 8951.04
- Total Equity
- 15012.28
- Tangible Book Valueper Share Common Eq
- 127.03
- Period
- 2019
- Cashfrom Operating Activities
- 1691.14
- Cashfrom Investing Activities
- -1668.68
- Cashfrom Financing Activities
- -348.72
- Net Changein Cash
- -345.11
- Period
- 2025-03-31
- Total Revenue
- 6729.69
- Selling/ General/ Admin Expenses Total
- 1233.1
- Depreciation/ Amortization
- 308.73
- Other Operating Expenses Total
- 1769.98
- Total Operating Expense
- 5500.83
- Operating Income
- 1228.86
- Net Income Before Taxes
- 1504.3
- Net Income
- 1221.84
- Diluted Normalized EPS
- 15.12
- Period
- 2025-03-31
- Total Assets
- 37387.04
- Total Liabilities
- 6193.59
- Total Equity
- 31193.45
- Tangible Book Valueper Share Common Eq
- 324.5
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 5004.98
- Cashfrom Investing Activities
- -3691.14
- Cashfrom Financing Activities
- -1292.79
- Net Changein Cash
- 30.31
- Period
- 2024-12-31
- Total Revenue
- 7072.97
- Selling/ General/ Admin Expenses Total
- 1197.62
- Depreciation/ Amortization
- 279.8
- Other Operating Expenses Total
- 1622.35
- Total Operating Expense
- 5363.85
- Operating Income
- 1709.12
- Net Income Before Taxes
- 1916.09
- Net Income
- 1570.51
- Diluted Normalized EPS
- 19.43
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 7051.02
- Selling/ General/ Admin Expenses Total
- 1207.88
- Depreciation/ Amortization
- 271.74
- Other Operating Expenses Total
- 1674.54
- Total Operating Expense
- 5437.17
- Operating Income
- 1613.85
- Net Income Before Taxes
- 1789.06
- Net Income
- 1302.53
- Diluted Normalized EPS
- 16.12
- Period
- 2024-09-30
- Total Assets
- 34655.28
- Total Liabilities
- 6293.18
- Total Equity
- 28362.1
- Tangible Book Valueper Share Common Eq
- 287.92
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 2055.44
- Cashfrom Investing Activities
- -710.31
- Cashfrom Financing Activities
- -1182.8
- Net Changein Cash
- 177.57
- Period
- 2024-06-30
- Total Revenue
- 6693.94
- Selling/ General/ Admin Expenses Total
- 1194.23
- Depreciation/ Amortization
- 246.68
- Other Operating Expenses Total
- 1591.03
- Total Operating Expense
- 5224.82
- Operating Income
- 1469.12
- Net Income Before Taxes
- 1611.36
- Net Income
- 1177.64
- Diluted Normalized EPS
- 14.57
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 6163.24
- Selling/ General/ Admin Expenses Total
- 1084.23
- Depreciation/ Amortization
- 288.34
- Other Operating Expenses Total
- 1713.03
- Total Operating Expense
- 5135.72
- Operating Income
- 1027.52
- Net Income Before Taxes
- 1259.26
- Net Income
- 939.04
- Diluted Normalized EPS
- 11.63
- Period
- 2024-03-31
- Total Assets
- 32717.82
- Total Liabilities
- 6011.39
- Total Equity
- 26706.43
- Tangible Book Valueper Share Common Eq
- 272.41
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 4133.91
- Cashfrom Investing Activities
- -2988.03
- Cashfrom Financing Activities
- -1200.43
- Net Changein Cash
- -48.99
- Period
- 2023-12-31
- Total Revenue
- 6603.81
- Selling/ General/ Admin Expenses Total
- 1068.13
- Depreciation/ Amortization
- 233.43
- Other Operating Expenses Total
- 1568.62
- Total Operating Expense
- 5284.53
- Operating Income
- 1319.28
- Net Income Before Taxes
- 1473.81
- Net Income
- 1055.9
- Diluted Normalized EPS
- 14.82
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Cipla Technical
Moving Average
SMA
- 5 Day1502.48
- 10 Day1505.89
- 20 Day1492.06
- 50 Day1498.1
- 100 Day1474.04
- 300 Day1510.63
Cipla Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sun Pharmaceutical Industries
- 1668
- 6.7
- 0.4
- 1960.2
- 1471.05
- 400355.95
- Divis Laboratories
- 6581.05
- 15.3
- 0.23
- 6859.8
- 4396.6
- 174885.99
- Cipla
- 1509.8
- 6.95
- 0.46
- 1702
- 1310.05
- 121919.33
- Dr Reddys Laboratories
- 1337.1
- -0.25
- -0.02
- 1420.2
- 1025.9
- 111585.28
- Torrent Pharmaceuticals
- 3233.95
- 56.6
- 1.78
- 3589.95
- 2755
- 109446.65
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sun Pharmaceutical Industries
- 33.58
- 5.52
- 13.02
- 16.24
- Divis Laboratories
- 79.76
- 11.77
- 18.08
- 25.96
- Cipla
- 22.99
- 3.88
- 15.18
- 14.74
- Dr Reddys Laboratories
- 19.4
- 3.27
- 17.62
- 15.81
- Torrent Pharmaceuticals
- 55.56
- 14.11
- 22.03
- 14.14
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-May-25
- Audited Results & Final Dividend
- 28-Jan-25
- Quarterly Results
- 29-Oct-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 10-May-24
- Audited Results & Final Dividend
- 25-Jan-24
- Quarterly Results
- 22-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 26-Jul-23
- Quarterly Results
- 12-May-23
- Audited Results & Final Dividend
- Meeting Date
- Announced on
- Purpose
- 16-Jul-25
- 13-May-25
- AGM
- 15-Oct-24
- 17-Sept-24
- POM
- 20-Aug-24
- 10-May-24
- AGM
- 10-Aug-23
- 12-May-23
- AGM
- 26-Aug-22
- 29-Jul-22
- AGM
- 25-Aug-21
- 27-Jul-21
- AGM
- 27-Mar-21
- 23-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 13-May-25
- 27-Jun-25
- 27-Jun-25
- 13
- 14-May-25
- 27-Jun-25
- 27-Jun-25
- 3
- 10-May-24
- 02-Aug-24
- 02-Aug-24
- 13
- 12-May-23
- 21-Jul-23
- 21-Jul-23
- 8.5
- 27-Jul-22
- 10-Aug-22
- 08-Aug-22
- 5
- 14-May-21
- -
- 09-Aug-21
- 5


